Mozhuo Biotech Secures RMB 150 Million Series A Funding to Accelerate Commercialization of Multi-Omics Single-Cell Sequencing Platform

VCBeat (WeChat: vcbeat) has learned that MobiDrop, a leader in single-cell sequencing, recently announced the completion of its RMB 150 million Series A financing round., led by Huagai Capital, with follow-on investments from Source Code Capital and existing shareholder Proxima Capital. The funds raised in this round will be used to continuously enrich and improve MobiDrop’s MobiNova™ single-cell multi-omics product line, including systematic single-cell sequencing solutions such as transcriptomics, immune VDJ analysis, and ATAC-seq, while accelerating product launches and commercial promotion to expand MobiDrop’s single-cell sequencing products from the research sector into drug development and clinical testing.

In terms of national policy, the "14th Five-Year" National Key R&D Program for the Biomedical Industry explicitly includes "the development of microbial single-cell imaging and rapid species identification, as well as single-cell sorting and sequencing technologies," underscoring the critical importance of advancing single-cell sequencing technologies. Single-cell sequencing offers high-throughput, high-precision solutions that enable the study of gene expression at the cellular and subcellular levels, holding pivotal significance for the gene sequencing industry and earning it the reputation of being the "microscope of the sequencing world." Against this backdrop, MobiDrop’s recent financing and product portfolio strategically align with the trends and developmental directions of China’s frontier science and technology strategy.

In response, Dr. Pei Hao, Founder and CEO of MobiDrop, stated, “We extend our gratitude to Huagai Capital, Source Code Capital, Proxima Capital, and all investors for their trust and support in the MobiDrop team. Leveraging years of technological expertise, MobiDrop is dedicated to serving precision medicine and life science research and is poised to launch its MobiNova™ single-cell multi-omics product line. This round of financing will significantly accelerate MobiDrop’s single-cell sequencing business. We anticipate that related products, including instruments, reagents, and bioinformatics analysis software, will undergo public beta testing this December. We also look forward to engaging in deep collaborations with industry experts and partners.”

David Weitz, a member of the three U.S. National Academies, a foreign member of the Chinese Academy of Engineering, and a tenured professor at Harvard University, served as the doctoral supervisor for Hao Pei, CEO of MobiDrop, and is the inventor of single-cell technology. As a founding shareholder and Chief Scientific Officer of MobiDrop, Professor Weitz stated, “Single-cell sequencing technology is a revolutionary achievement that emerged from my laboratory at Harvard. MobiDrop was founded by two of my outstanding doctoral students and possesses a world-leading microfluidics technology platform with extensive technical expertise in the field of single-cell sequencing. I congratulate MobiDrop on the successful completion of its Series A financing round and am delighted to witness their rapid commercialization progress. I will continue to support MobiDrop’s future development.” The MobiNova™ high-throughput single-cell sequencing system launched by MobiDrop can stably achieve cell isolation and has realized the world’s first application of single-cell sequencing for gut microbiota, marking the company’s mastery and breakthrough of core key technologies in high-throughput single-cell sequencing.

Mr. Zhang Yi, Managing Partner of Huagai Capital’s Healthcare Yangtze River Delta Fund, stated, “We are highly committed to collaborating with entrepreneurial teams that possess forward-thinking visions and deep industry insights to build a more robust healthcare ecosystem. We have been closely monitoring the single-cell sequencing sector for several years. Among early-stage startups we have evaluated, MobiDrop stands out as the most technically solid, with the clearest technological roadmap and the most pragmatic business approach. Led by David Weitz, an academician of four Chinese and American academies, the company holds immense growth potential. We believe that MobiDrop will play a leading role in this rapidly evolving field, helping to revitalize and advance China’s biopharmaceutical industry.”

Li Zhe, Managing Partner at Proxima Capital, stated, “As an outstanding innovative molecular diagnostics company in China, MobiDrop leverages its team’s industry-leading microfluidics technology to build a precise and rapid new platform for molecular diagnostics and life sciences research. We are delighted to see MobiDrop rapidly launch blockbuster products in the field of single-cell analysis. Proxima Capital remains firmly optimistic about the MobiDrop team’s strategic layout and breakthrough innovations in digital microfluidics. We will continue to facilitate MobiDrop’s integration with leading medical ecosystems to support the rapid growth of its business.”

An investor from Source Code Capital stated, “Single-cell technology is revolutionary for life science research. The maturation of high-throughput single-cell sequencing technology has provided fertile ground for translational medicine research. With globally leading microfluidics technology, robust engineering development capabilities, and comprehensive commercialization expertise, the MobiDrop team is well-positioned to continue delivering superior single-cell products to the precision medicine industry.”

MobiDrop was founded at Harvard University in 2018. Leveraging a proprietary portfolio of cutting-edge third-generation microfluidics technologies, MobiDrop is committed to developing novel molecular diagnostics and life science research platforms that are more precise, rapid, and practical. By enhancing diagnostic and testing quality and advancing life science research, the company provides more efficient solutions for researchers, physicians, and patients. Over the past three years, MobiDrop has established a globally leading multi-omics high-throughput single-cell sequencing platform, partnering with dozens of institutions, including top-tier hospitals, renowned pharmaceutical companies, and major research institutes.

Huagai Capital envisions becoming the most trusted capital partner for entrepreneurs and investors, focusing on private equity investments in three major sectors: healthcare, TMT (Technology, Media, and Telecom), and digital innovation. The firm has managed a cumulative fund size of approximately RMB 20 billion, with 18 of its portfolio companies successfully listed. Its healthcare funds focus on biopharmaceuticals, medical devices, and healthcare services, prioritizing industry M&A consolidation within the healthcare sector as well as investment opportunities in high-growth, high-tech enterprises at early to mid-stages.

Proxima Capital is a specialized investment firm focused on medical technology and biotechnology, dedicated to serving exceptional innovative healthcare technology companies with significant growth potential. Managed and operated by a professional team with extensive experience in the medical industry, Proxima Capital boasts diverse and international expertise, professional backgrounds, and industry networks. The firm has established a leading healthcare entrepreneurship ecosystem, helping its portfolio companies connect with high-quality clinical and industrial resources, achieving remarkable experience and results.

Source Code Capital was founded in the spring of 2014, dedicated to identifying and empowering leading enterprises amidst the wave of technological revolution. The firm currently manages USD 2.5 billion and RMB 8.8 billion. Source Code Capital adheres to first-principles thinking and deep research to drive its investment decisions. Guided by its “Three Horizontal, Nine Vertical” investment framework, it has strategically invested in over 200 companies, driven by three core themes: “Internet+,” “Intelligence+,” and “Globalization+.”